ALX Oncology, a Dublin and California-headquartered biotechnology company in which the State has a stake, has raised $63.2 million from a public offering.
The clinical-stage immuno-oncology company old 8,663,793 shares of common stock price $6.38 per share with proceeds from the offering to be used fund the continued clinical development of its lead candidate Evorpacept. Founded in 2015 as Alexo Therapeutics, ALX is focused on helping patients fight cancer by developing a range of product candidates.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: